Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The prognosis of advanced metastatic melanoma remains poor although a breakthrough has been
achieved with the novel anti-CTLA-4 treatment (ipilimumab) for a subset of patients.
Unfortunately, due to immune resistance, the majority of patients do not obtain long-lasting
clinical benefit. Radiotherapy is able to interfere with immune resistance by inducing
immunogenic cell death. Preclinical evidence indicates that combining radiotherapy with
anti-CTLA-4 treatment increases response rates compared to single agent treatment. These data
are supported by several spectacular clinical cases and one retrospective study. The
investigators hypothesize that combining ipilimumab with radiotherapy will result in a higher
response rate compared to ipilimumab or radiotherapy in monotherapy. Given the complexity of
the interaction in anti-tumor immunity, the first goal of this project is to assess the
safety of the combined treatment.